Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine a in Renal Transplant Patients
Elens, Laure Hesselink, Dennis A Bouamar, Rachida Budde, Klemens de Fijter, Johannes W De Meyer, Martine Mourad, Michel Kuypers, Dirk Haufroid, Vincent van Gelder, Teun van Schaik, Ron H N
Therapeutic Drug Monitoring vol:35 issue:5 pages:709-709
13th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology location:Salt Lake City date:sept 22-26, 2013
The P450 oxidoreductase (POR)*28 variant allele has been associated with altered cytochrome P450 3A enzyme activities. Both CYP3A5 and CYP3A4 are involved in the metabolism of calcineurin inhibitors and recent data show that POR*28 may explain part of the variability observed in tacrolimus (Tac) pharmacokinetics. The aim of this study was to investigate the impact of the POR*28 allele on Tac and cyclosporine A (CsA) immunosuppressive therapies.